United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy

United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage pipeline. Management expects to exit 2027 with a $1 billion quarterly revenue run rate from currently approved products, providing a strong commercial base. Ralinepag and Nebulized Tyvaso in IPF are near-term pipeline catalysts, with multi-billion dollar peak sales potential if approved. Risks include FDA approval uncertainty, margin compression, US sales concentration, and significant insider selling, but UTHR’s consistent cash flow and profitability mitigate existential concerns.

This is my fourth look at United Therapeutics (UTHR) following my third, 02/2026's "United Therapeutics: In Progress -- New Organs For Old At Scale". In At Scale, I rated United as a hold; it has since risen a nice ~16%, taking This article was written by Out of Ignorance 7.72K Followers Follow Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.